Assess the Safety and Immunogenicity of PNEUMOSIL® Vaccine in Healthy Vietnamese Children, 6 Weeks to 24 Months of Age
Not Applicable
- Conditions
- Streptococcus PneumoniaVaccine Preventable Disease
- Interventions
- Biological: PNEUMOSIL®
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- Vabiotech
- Target Recruit Count
- 300
- Registration Number
- NCT05140720
The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks
Not Applicable
Completed
- Conditions
- DiphtheriaTetanusPertussisHepatitis BHaemophilus Influenzae Type B
- Interventions
- Biological: Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval
- First Posted Date
- 2019-04-30
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- Vabiotech
- Target Recruit Count
- 222
- Registration Number
- NCT03931239
- Locations
- 🇻🇳
Hung Yen, Kim Dong, Hung Yen, Vietnam
© Copyright 2025. All Rights Reserved by MedPath